



Original article

Efficacy of curcumin in the treatment of experimental vulvovaginal candidiasis



Jessica Tauany Andrade^a, Geisa Fantini de Figueiredo^b, Luisa Ferreira Cruz^b, Sarah Eliza de Morais^b, Carla Daiane Ferreira Souza^a, Flávia Carmo Horta Pinto^c, Jaqueline Maria Siqueira Ferreira^a, Marcelo Gonzaga de Freitas Araújo^{b,*}

^a Laboratory of Medical Microbiology, Federal University of São João Del-Rei, Campus Centro Oeste Dona Lindu, Divinópolis, Minas Gerais, Brazil

^b Laboratory of Pharmacology, Federal University of São João Del-Rei, Campus Centro Oeste Dona Lindu, Divinópolis, Minas Gerais, Brazil

^c Natural Sciences Department, Federal University of São João Del-Rei, Campus Dom Bosco, São João Del-Rei, Minas Gerais, Brazil

ARTICLE INFO

Article history:

Received 6 February 2018

Accepted 22 January 2019

Available online 19 November 2019

Keywords:

Antifungal activity

Candida albicans

Curcumin

Ergosterol

Vulvovaginal candidiasis

ABSTRACT

Background: *Candida albicans* is the main agent that causes vulvovaginal candidiasis. Resistance among isolates to azole antifungal agents has been reported.

Aims: Due to the well-known antifungal potential of curcumin, the purpose of this work was to evaluate the *in vitro* anticandidal activity of curcumin and its effect in the treatment of experimental vulvovaginal candidiasis.

Methods: The anticandidal activity of curcumin was investigated against eight *Candida* strains by the broth microdilution assay, and its mechanism of action was evaluated by testing the binding to ergosterol. Then, the effect of curcumin in the treatment of vulvovaginal candidiasis was evaluated in an immunosuppressed, estrogen treated rat model.

Results: Curcumin showed minimum inhibitory concentration values of 125–1000 µg/ml, and the best result was observed against *Candida glabrata*. The compound was shown to be able to bind to the ergosterol present in the membrane, event that may be the mechanism of action. In addition, in the *in vivo* model of vulvovaginal candidiasis with *C. albicans*, treatments reduced the vaginal fungal burden in infected rats after seven days of treatment with different doses.

Conclusions: Curcumin could be considered a promising effective antifungal agent in the treatment of vulvovaginal candidiasis.

© 2019 Asociación Española de Micología. Published by Elsevier España, S.L.U. All rights reserved.

Eficacia de la curcumina en el tratamiento de la candidiasis vulvovaginal experimental

RESUMEN

Antecedentes: *Candida albicans* es la principal causante de la candidiasis vulvovaginal y algunos aislamientos pueden presentar resistencia a los antifúngicos azólicos.

Objetivos: Debido al conocido potencial antifúngico de la curcumina, el objetivo de este trabajo fue evaluar su actividad anti-*Candida in vitro* y su efecto en el tratamiento de la candidiasis vulvovaginal experimental.

Métodos: La actividad anti-*Candida* de la curcumina se evaluó frente a ocho cepas de *Candida* mediante un ensayo de microdilución en caldo, y su mecanismo de acción se estudió por una prueba de unión a ergosterol. Posteriormente se evaluó el efecto de la curcumina en el tratamiento de la candidiasis vulvovaginal con un modelo de rata inmunosuprimida, tratada con estrógenos.

Palabras clave:

Actividad antifúngica

Candida albicans

Curcumina

Ergosterol

Candidiasis vulvovaginal

* Corresponding author.

E-mail address: mgsfaraujo@ufsj.edu.br (M.G.F. Araújo).

Resultados: La curcumina mostró valores de concentración inhibitoria mínima de 125–1.000 µg/ml, y el mejor resultado se observó frente a *Candida glabrata*. El compuesto demostró ser capaz de unirse al ergosterol de la membrana, lo que podría ser su mecanismo de acción. Además, en el modelo *in vivo* de candidiasis vulvovaginal con *C. albicans*, los tratamientos redujeron la carga fúngica vaginal en ratas infectadas después de siete días de tratamiento con diferentes dosis.

Conclusiones: La curcumina podría considerarse un agente antifúngico eficaz prometedor en el tratamiento de la candidiasis vulvovaginal.

© 2019 Asociación Española de Micología. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

The most prevalent candidiasis-causing species is *Candida albicans*.⁴⁵ *C. albicans* is a dimorphic commensal fungus of mucosal surfaces, commonly found in the gastrointestinal and genitourinary tracts. It is the main agent that causes vulvovaginal candidiasis (VVC). The incidence of this disease is high, affecting 75% of all women at least once during their life-time. The risks associated with the acute form of VVC include imbalances in reproductive hormones caused by pregnancy, the use of oral contraceptives, and hormone replacement therapy, as well as the use of large spectrum antibiotics, diabetes, immunosuppression therapy, and stress.^{8,17} Some data suggest that the local immune response provides important protection during vaginitis.^{27,31} The vaginal epithelium plays an essential function as an active barrier that protects the female reproductive tract against the pathogenicity of different microorganisms. The expression of immunity receptors in those cells provides sensitivity to different pathogens, and their ability to produce some inflammation mediators leads to the course of local inflammation.^{4,27}

Despite the advances in antifungal therapy, there are many problems related to the available drugs. Some antifungals commonly used to treat VVC, such as azoles, are potentially hepatotoxic. Those drugs have been reported to produce reproductive and developmental toxicity in both humans and laboratory animals.^{18,23,42} Furthermore, isolates of *Candida* are reported to be slightly susceptible to one or more azoles.^{3,40,44} The search for effective compounds with a lower toxicity index leads to investigate natural products as promising candidates in antifungal therapy. The disturbing reality of the progressive emergence of less susceptible strains to antimicrobials also drives this search. A variety of chemical compounds with antimicrobial properties are present in plants, and scientific researches to determine whether those compounds have antibiotic properties against resistant pathogens are necessary.^{2,20,47}

Species of *Curcuma* are widely found in Asia, and their roots are used in food and traditional medicine.³⁴ Their therapeutic properties are linked to curcuminoids, polyphenolic compounds, being curcumin (1,7-bis[4-hydroxy-3-methoxyphenyl]-1,6-heptadiene-3,5-dione) the most abundant.²¹ Curcumin is well-known to have therapeutic potential due to its antioxidant, anticarcinogenic, antimutagenic, and antimicrobial activities, among others.⁴⁸ Some reports have shown that curcumin has antifungal potential against different human pathogens.^{28,30} Regarding its activity against *Candida* species, curcumin was shown to be more efficient than fluconazole in the inhibition of oral epithelia fungal adhesion.²⁶ In another study³⁷ it was reported that curcumin acts as an antifungal agent *via* the generation of oxidative stress, and inhibits hyphae development by targeting TUP1. In addition, the mechanisms of action of curcumin on *Candida* that have already been described include the inhibition of hyphae development through the action on the TUP1 gene,⁴² the reduction of ergosterol biosynthesis, the functional modulation of fungal PM-ATPase and the inhibition of fungal exoenzymes SAP (aspartate proteases).^{24,25} Besides the antifungal effectiveness, there is

evidence that curcumin acts as an anti-inflammatory agent by inhibiting cyclooxygenases and lipoxygenases, and also regulates the production of pro-inflammatory cytokines.^{9,22}

Since the pharmacological potential of curcumin is notable, and there is not a robust evidence on the anti-*Candidal* effect of curcumin *in vivo*, we investigated the antifungal potential of curcumin and its mechanism of action *in vitro* and in the therapeutic treatment of VVC in an immunosuppressed rat model.

Materials and methods

Candida strains, animals and drug

Three strains belonged to the American Type Culture Collection (*C. albicans* ATCC 10231, *Candida glabrata* ATCC 2001, *Candida krusei* ATCC 34135), and 5 clinical isolates of *Candida dubliniensis* were obtained from vaginal fluid specimens; the identification was carried out by conventional methods, including growth on chromogenic medium (CHROMagar Paris, France) according to the manufacturer's instructions. The *in vivo* assay was performed using female Wistar rats (*Rattus norvegicus*), which were obtained from the Central Animal Facility of Federal University of São João Del-Rei (UFSJ), Campus Dom Bosco. Curcumin (from *Curcuma longa*, ≥65% of purity), the tested compound in this study, was obtained commercially from Sigma–Aldrich®, Brazil.

Growth conditions and inocula

All *Candida* strains were grown on Sabouraud dextrose agar (SDA) (Acumedia®, Brazil) for 48 h at 35–37 °C. Each inoculum of *Candida* used in the experiments was standardized to 1×10^6 CFU/ml by adjusting the optical density to 0.08–0.1 at 530 nm (Biotek®, Brazil).² *C. albicans* ATCC 10231 was used for the *in vivo* infection.

In vitro susceptibility test

The minimum inhibitory concentration (MIC) was determined by the microdilution method according to documents M38-A2 and M27-A3 of the Clinical and Laboratory Standards Institute,¹⁰ with minor modifications.^{1,29,41} The initial concentration of curcumin was prepared at 2000 µg/ml (ethanol was used as solvent) and 0.02 ml of this solution was added to a 96-well microtitre plate containing Sabouraud dextrose broth (SDB) (Acumedia®, Brazil). The initial test concentration was serially two-fold diluted. Each well was inoculated with 0.1 ml of a suspension containing 2.5×10^3 CFU/ml. The antifungals ketoconazole (Sigma–Aldrich®, Brazil) and nystatin (Sigma–Aldrich®, Brazil) were included as positive controls and ethanol (solvent) was included as the negative control. The plates were incubated for 48 h at 37 °C. The MIC of each compound for every isolate was determined following the addition of 0.05 ml of 2% triphenyltetrazolium chloride (TTC, Sigma–Aldrich®, Brazil). Yeast growth was displayed by a change




Fig. 1. Schematic representation of the experimental design. CPA: cyclophosphamide treatment; Est: estradiol cypionate treatment. *The vaginal load of *C. albicans* was evaluated through vaginal lavage on the fourth and eighth day in order to evaluate the curcumin effectiveness after three and seven days of treatment, respectively **Animals were treated twice per day for seven consecutive days.

to a red color. MIC was defined as the lowest concentration of compound showing no visible fungal growth after the TTC reaction. The minimal fungicidal concentration (MFC), in turn, was determined as the absence of visible colonies in Sabouraud dextrose agar (SDA), as previously described.¹⁹ All experiments were performed in triplicate.

Membrane ergosterol as target of antifungal activity

The MIC of curcumin against *C. albicans* ATCC 10231, *C. glabrata* ATCC 2001 and *Candida krusei* ATCC 34135 was determined following a standard reference method as explained above, in the absence and presence of exogenous ergosterol (200 µg/ml) to determine whether curcumin binds to the fungal membrane sterol. If the activity of curcumin was caused by binding to ergosterol, the exogenous ergosterol would prevent curcumin binding to the fungal membrane's ergosterol. As a consequence, MIC values were enhanced in the presence of exogenous ergosterol.¹⁵ Nystatin at an initial concentration of 1000 µg/ml was used as a control drug. Caspofungin (Sigma–Aldrich®, Brazil), an antifungal that interfere with the fungal cell wall, was used at an initial concentration of 1000 µg/ml as a negative control. The MIC was determined after 48 h of incubation. All experiments were performed in triplicate.

Experimental VVC

Female Wistar rats (body weight 100–150 g) were collectively housed in the experimental room of the Laboratory of Pharmacology of UFSJ-Campus Centro Oeste (25 °C ± 1 °C, 12-h dark–light cycle). All applicable national and institutional guidelines for the care and use of animals were followed. Animals were maintained in the environmentally controlled room for at least 5 days before the experiments started. The protocol was approved by the Animal Experimentation Ethics Committee of the Universidade Federal de São João Del-Rei (Protocol 029/2013).

The rat model of vaginal infection was established to obtain a chronic and homogeneous infection.² Fig. 1 presents a schematic representation of the experimental design. Animals were immunosuppressed by the administration of one dose of cyclophosphamide (Sigma®, 50 mg/kg b.w.) and estrus was induced by the subcutaneous administration of estradiol cypionate (Pfizer®, Brazil) at a dose of 0.2 mg/ml once daily for four days before the infection was induced. Rats were inoculated intravaginally with 0.1 ml of *C. albicans* ATCC 10231 (5×10^7 CFU/ml) using a micropipette with disposable tips. Two days after inoculation (day 0) the vaginal load of *C. albicans* was evaluated through vaginal lavage with 0.1 ml of sterile saline, and determined by the CFU assay on SDA to verify whether the infection had been established. The infection was considered sufficient if a mean count for the vaginal lavage cultures from each rat was at least 10^3 CFU/ml.

Therapeutic treatment

To evaluate the effect of curcumin in VVC, three different concentrations of the compound solution and its controls were administered intravaginally to the infected animals. Wistar females ($n = 42$) were randomized equally into the following seven groups: Group 1: non-infected animals; Group 2: infected animals, not treated; Group 3: infected animals treated with miconazole vaginal cream (0.1 ml) (MCZ, 10 mg/g, Medley®, Brazil); Group 4: infected animals treated with 0.25% of curcumin solution (0.1 ml); Group 5: infected animals treated with 0.5% of curcumin solution (0.1 ml); Group 6: infected animals treated with 1% of curcumin solution (0.1 ml); and Group 7: infected animals treated with a 20% ethanol solution (vehicle control group) (0.1 ml). Treatments were administered to the infected animals twice a day for seven consecutive days. One, four and eight days after the infection was established, the vaginal load of *C. albicans* was also evaluated to verify the effectiveness of the treatments. On day 8, the animals were euthanized and vaginas were longitudinally removed. All vaginal sections were stained with hematoxylin and eosin (H&E) and observed under light microscopy. From the histological slides stained by H&E, a quantitative analysis of the total inflammatory cells (polymorphonuclear and mononuclear) was performed using a digital image analyzer (Motic Images Plus 2.0 ML); the images were generated by a Zeiss Axiolab microscope connected to a camera (Moticam 580 5.0 MP) interconnected to a computer scanner. The images were obtained from the connective tissue of the vaginal mucosa, where the leucocytes were identified by their characteristic morphology. A total of 10 fields per slide at 400x magnification were analyzed through the Image J Program (NIH, BETHESDA, USA). The results of the quantitative analysis in each group were expressed as the mean ± standard deviation of inflammatory cells/mm².

Statistical analysis

To verify the evolution in the reduction of the vaginal fungal load, analyses comparing the means obtained with curcumin on the third and seventh days with that of the first day after the infection were performed. Data obtained from the groups treated with curcumin were also compared with those from non-infected, infected-not treated groups, and vehicle control group. For the quantitative histological analyses, means between groups were compared. The results were analyzed statistically by the analysis of variance (ANOVA) for completely randomized experiments, with the calculation of the F statistic and the subsequent *p* values. In the cases in which *p* value was less than 0.05, treatment means were compared by the Tukey test for multiple comparison analysis between groups, and the minimum significant difference was calculated for $\alpha = 0.05$. GraphPad Prism 7® software was used to perform the statistical analyses.

Table 1
In vitro antifungal activity of curcumin.

Candida strains	MIC curcumin ^a	MFC curcumin ^a	MIC ^a ketoconazole ^b	MIC ^a nystatin ^b
<i>C. albicans</i> ATCC 10231	1000	>1000	62.5	3.9
<i>C. glabrata</i> ATCC 2001	125	>1000	1.95	3.9
<i>C. krusei</i> ATCC 34135	500	>1000	0.97	7.8
<i>C. dubliniensis</i> clinical isolate 11763	>1000	>1000	0.97	ND
<i>C. dubliniensis</i> clinical isolate 1083	>1000	>1000	0.97	ND
<i>C. dubliniensis</i> clinical isolate 1203	1000	>1000	0.97	ND
<i>C. dubliniensis</i> clinical isolate 1417	1000	>1000	0.97	ND
<i>C. dubliniensis</i> clinical isolate 1252	1000	>1000	0.97	ND

^a Values in µg/ml.^b Positive control; ND: not determined.**Table 2**
In vitro antifungal activity of curcumin against *Candida* species with and without exogenous ergosterol.

	<i>C. albicans</i> ATCC 10231		<i>C. glabrata</i> ATCC 2001		<i>C. krusei</i> ATCC 34135	
	MIC ^a	MIC with ergosterol ^a	MIC ^a	MIC with ergosterol ^a	MIC ^a	MIC with ergosterol ^a
Curcumin	1000	2000	125	125	500	500
Nystatin	3.9	31.25	3.9	31.25	7.8	31.25
Caspofungin	3.9	3.9	0.5	0.5	0.0625	0.0625

^a Values in µg/ml. Nystatin: positive control. Caspofungin: negative control.**Table 3**
Vaginal fungal burden in all the studied animals according to the different groups.

Groups	Day 0		Day 3		Day 7	
	Infected animals (%)	Log CFU/ml ± SD	Infected animals (%)	Log CFU/ml ± SD	Infected animals (%)	Log CFU/ml ± SD
Infected control	6/6 (100)	3.25 ± 0.20	6/6 (100)	2.04 ± 0.04	5/6 (83.3)	3.00 ± 0.07
Positive control	6/6 (100)	4.94 ± 0.06	3/6 (50)	3.89 ± 0.03	0/0 (0)	0.00 ± 0.00*
Curcumin 0.25%	6/6 (100)	2.46 ± 0.13	3/6 (50)	1.61 ± 0.02*	0/0 (0)	0.00 ± 0.00*
Curcumin 0.5%	6/6 (100)	2.48 ± 0.07	0/6 (0)	0.00 ± 0.00*	0/0 (0)	0.00 ± 0.00*
Curcumin 1%	6/6 (100)	3.53 ± 0.02	4/6 (66.6)	0.49 ± 0.01*	0/0 (0)	0.00 ± 0.00*
Vehicle	6/6 (100)	2.64 ± 0.22	6/6 (100)	2.72 ± 0.72	5/6 (83.3)	3.20 ± 0.27

* Statistically significant difference from the values obtained on day 0 ($p < 0.05$); SD = standard deviation.

Results

Antifungal activity and mechanisms of action

The MIC value of curcumin against *C. glabrata* was 125 µg/ml, but a concentration of 500 µg/ml was required to achieve the same effect for *C. krusei*. Similar growth inhibition endpoints (1000 µg/ml) with *C. albicans* and the clinical isolates of *C. dubliniensis* recovered from VVC patients were observed. Table 1 shows the results of MIC and MFC of curcumin with the different *Candida* species, as well as the MIC values with the antifungal controls (ketoconazole and nystatin).

The results of the action of curcumin on membrane ergosterol indicate that curcumin, as well as nystatin, can bind to *C. albicans* ergosterol since the presence of exogenous ergosterol increased the MIC values (Table 2), thus suggesting the possible mechanism of action. As expected, caspofungin, the negative control, did not show any MIC increase in the presence of exogenous ergosterol. In this study, the curcumin could not bind to *C. krusei* and *C. glabrata* ergosterol since the presence of exogenous ergosterol did not show increased MIC values.

Treatment of VVC

The immunosuppressed and estrogen-dependent rats were infected with *C. albicans*, and fungal burden was assessed after 2 days (on day 0). Once the infection was established, we examined the activity of different concentrations of curcumin and MCZ in those animals in which VVC was achieved. On the 3rd day after the beginning of the treatment a new quantification of the fungal

burden (through a vaginal lavage) was carried out. In the group of infected and untreated animals and in those treated with solvent ethanol (vehicle control), the fungal burden remained high in five animal out of six during all the study time. In contrast, in the groups treated with different concentrations of curcumin (0.25, 0.5 and 1%) the fungal burden was significantly reduced. On day 7th after the beginning of the treatment, *C. albicans* was detected in the infected and vehicle control groups at significantly higher levels. The three groups treated with curcumin showed a complete clearance of fungal load on the 7th day after infection (Table 3). The treatment with MCZ exerted the complete clearance of the yeasts on the last day of treatment. Fungal load data are presented in log CFU/ml.

Histological analysis of the vaginal mucosa sections stained with H&E of all the animals was performed by light microscopy; representative images are shown in Fig. 2. We observed histologically normal vaginal mucosa in the uninfected group, while in the infected non-treated group the highest concentration of an inflammatory infiltrate in the lamina propria (below the epithelium) was observed. The histological study of the groups treated with 0.25 and 0.5% curcumin showed inflammatory infiltrate in the vaginal mucosa, with polymorphonuclear infiltration predominantly. The group treated with 1% curcumin showed a reduction in the mucosal inflammatory infiltrate. Regenerative changes associated with the restoration of the vaginal mucosa following MCZ treatment could be seen. Quantitative analysis of sections stained with H&E showed a reduction in the total inflammatory cells (polymorphonuclear and mononuclear) in the group treated with 1% curcumin, with a reduction proportional to the increase in the concentration of curcumin. The group treated with 1% curcumin showed a significant reduction in the number of inflammatory cells when compared to the infected-not treated group (Fig. 3).




Fig. 2. Representative photomicrographs of histological analyses of vaginal mucosa sections after different treatments: (A) non-infected animals (negative control) – vaginal mucosa with normal aspect; (B) infected and untreated animals – presence of inflammatory infiltrate in the lamina propria; (C) Infected animals treated with ethanol solution – presence of inflammatory infiltrate in the mucosa with polymorphonuclear infiltration mainly; (D) infected animals treated with MCZ (positive control) – presence of inflammatory process with polymorphonuclear infiltration mainly; (E) Infected animals treated with 0.25% curcumin – inflammatory infiltrate in the vaginal mucosa with polymorphonuclear infiltration mainly; (F) infected animals treated with 0.5% curcumin – inflammatory infiltrate in the vaginal mucosa, with polymorphonuclear infiltration mainly; (G) infected animals treated with 1% curcumin – reduction in mucosal inflammatory infiltrate compared to 0.25% and 0.5% curcumin treatments. The black arrows point to polymorphonuclear leucocytes. The red arrows point to mononuclear leucocytes. H&E stain, 400× magnification.




Fig. 3. Quantitative analysis per group. Data are expressed as mean \pm standard deviation of inflammatory cells/mm². *Groups with significant difference ($p < 0.05$) when compared with the infected control (Tukey test with statistical difference at $p < 0.05$) do not differ from each other.

Discussion

Curcumin has been evaluated with regard to a variety of biological activities, showing antifungal activity against a number of fungal pathogens, such as *Paracoccidioides brasiliensis*, *Aspergillus*, *Sporothrix schenckii*, as well as different *Candida* species.^{24,26,30} Since the current antifungal drugs have limitations, the interest in discovering new and more effective drugs has increased, especially those from natural sources.

The compound exhibited antifungal activity against the three species of *Candida* included in this study, and fungistatic activity was noted. Curcumin showed activity against *C. glabrata* at a considerable concentration. An increase in the incidence of invasive candidiasis caused by non-*C. albicans* *Candida* species has been observed and it is associated with high mortality and antifungal resistance.⁴⁰ Among the non-*C. albicans* *Candida* species, *C. glabrata* stands out, having emerged as one of the most important opportunistic pathogens that are particularly capable of infecting a variety of places in the human body; this is the second most frequently isolated species in cases of VVC, preceded only by *C. albicans*.^{38,43,46} Several studies have reported the antifungal activity of curcumin. Martins et al.²⁶ showed that curcumin was able to inhibit the growth of several *Candida* species, and *C. albicans* was the most susceptible among the species studied. Furthermore, they demonstrated that curcumin dramatically inhibited the adhesion of *Candida* to epithelial cells. Other studies³⁶ showed a synergistic effect of curcumin in combination with antifungal agents. Sharma et al. (2010)³⁶ evaluated the *in vitro* antifungal effects of curcumin alone as well as in combination with azoles and polyenes against isolates of *C. albicans*. In wild type *C. albicans* curcumin showed a synergistic effect in combination with azoles (fluconazole and ketoconazole) and polyenes (amphotericin and nystatin). The MIC₈₀ of curcumin in combination with fluconazole showed a 32-fold reduction, in combination with ketoconazole showed a 64-fold reduction, and a 16-fold reduction was observed when combined with amphotericin B or nystatin. These results demonstrate an important synergistic effect of curcumin in combination with important antifungal agents used in the clinical practice. In a study performed by Neelofar et al.³⁰ curcumin promoted the growth inhibition of *C. albicans* by using high concentrations of the compound when compared with the effective concentrations of fluconazole. Here, we observed that *C. albicans* and the clinical strains showed sensitivity to curcumin, with fungistatic activity being observed under the present experimental conditions.

The major sterol component present in the fungal membrane is ergosterol, which plays qualitatively similar properties in fungal membranes as that cholesterol plays in mammalian cell membranes. Ergosterol serves as a bioregulator of membrane fluidity and asymmetry; consequently, the integrity of the cell membrane is dependent on these sterols.⁵ One of the proposed mechanisms of actions for antifungal agents is binding to membrane ergosterol, which leads to fungal cell disruption and a loss of intracellular content.³² In this work, we observed that the binding to membrane ergosterol might be the mechanism of action of curcumin against fungi. The cell membrane disruption in *Candida* by means of curcumin has been observed in other studies²⁴; this antifungal activity supports our results. The authors demonstrated that the leakage of potassium ions from the fungal cytosol and a dissipation in the membrane potential was detected by bis-(1,3-dibutyl-barbituric acid) trimethineoxonol [DiBAC4(3)] staining. These authors also investigated an increase in membrane permeability in curcumin-treated *C. albicans* with an influx of propidium iodide. Fluorescence analysis with 1,6-diphenyl-1,3,5-hexatriene supported the membrane-targeted mechanism of action indicating membrane disruption. Using calcein leakage assays from curcumin-treated large unilamellar vesicles and giant unilamellar vesicles, these authors found that curcumin has a membrane-active mechanism inducing the leakage of intracellular components through the flappy membrane. However, the effect on membrane ergosterol in our study was species-specific; the curcumin was able to bind to ergosterol only in *C. albicans* ATCC 10231. This fact shows that the binding of curcumin to ergosterol is not a single-action mechanism. The action of curcumin on ergosterol and other fungal cell components should be determined in future studies.

The therapeutic effect of curcumin was examined in an experimental animal model of VVC. It is known that *Candida* species cause opportunistic infections in hosts with altered physiological or immune responses.⁴⁶ In general, the development of mucosal infection models requires the use of systemic immunosuppression, which is a valid method for quickly inducing fungal colonization.¹¹ In rodent models, as well as human infection, these are stringently estrogen-dependent.³³ In women, VVC is extremely infrequent in the pre-pubertal period, while women become susceptible in the postmenopausal period following hormone replacement therapy. Estrogen exerts a multifunctional permissive role for vaginal candidiasis through a number of both host- and *Candida*-directed effects.^{7,39} Since the local immunity is also critical for anti-*Candida* defense in the vaginal mucosa, estrogen treatment is important because it transforms the epithelium to a pseudo-estrous phase and inhibits local immune defenses, increasing the glycogen content and thereby facilitating mucosal infection.⁶ Thus, rats must be placed under stable pseudo-estrous conditions to establish experimental vaginal infection; this is usually achieved by estrogen treatment, which is sufficient to allow *C. albicans* infection to occur. Using the same model, several studies have shown the effectiveness of natural products against *C. albicans* in the treatment of VVC.^{2,13,47}

As previously reported,² a *C. albicans* suspension containing 5×10^7 CFU/ml was sufficient to establish an infection when instilled into the vagina of immunosuppressed-hormone treated rats. Other studies showed that immunosuppressed rats in a prolonged pseudo-estrous state are particularly susceptible to fungal colonization in the vaginal mucosa.^{2,35} The animals were treated twice a day for seven days and the doses of curcumin were selected on the basis of MIC results and previous *in vitro* antifungal activity studies using this compound. As shown in Table 3, after the 3rd day, the treatment with curcumin at 0.5% was able to completely clear the fungal burden in all animals, while at 0.25% and 1% the fungal burden was reduced significantly ($p < 0.05$). On the 7th day, the infection was completely cleared in the groups treated with 0.25% and 1% curcumin. On the last day of treatment, the difference

was not statistically significant ($p > 0.05$) among the groups treated with curcumin and the one treated with miconazol, but differences were statistically significant when comparing with the infected-not treated and vehicle control groups. The inclusion of control groups was important to prove the test sensitivity and to ensure the curcumin effectiveness, since five animals remained infected in the infected-untreated group and in the vehicle control group during the entire study period.

The histological study of the non-treated group showed signs of tissue reaction related to the infection, since an intense concentration of inflammatory infiltrate was observed. The groups treated with curcumin exhibited a reduction in inflammatory infiltrates, being the degree of reduction proportional to higher concentrations. Some studies have described the anti-inflammatory potential of curcumin and its ability to interact with numerous molecular targets involved in inflammation, including the altered activity of enzymes, such as cyclooxygenases and lipoxygenases, by inhibiting the tumor necrosis factor (TNF) and the pro-inflammatory transcription nuclear factor kappa B (NF- κ B).^{14,16} Debata et al. (2013),¹² in a similar experiment with rats, treated the animals intravaginally for three weeks with a cream containing curcumin and then analyzed the results by histological analysis. The authors reported that the vaginal epithelium of the animals did not show any ulceration, areas of necrosis or micro-abscesses, and concluded that the intravaginal application of curcumin in a cream vehicle is feasible and safe.

In conclusion, the *in vitro* results highlight the potential of curcumin as an effective antifungal against *Candida* species growth, showing a similar mechanism of action to the commercial antifungal nystatin. Its efficacy in a VVC rat model suggests that curcumin may be an important compound for the treatment of this fungal infection, and that the development of a vaginal cream formulation containing this compound should be considered.

Ethical approval

All procedures performed in the studies involving animals were in accordance with the ethical standards of the institution or practice at which the studies were conducted.

Conflict of interest

The authors declare that they have no conflict of interest.

Acknowledgements

The authors are grateful to Fundação de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG) for the financial support which provided fellowships to S.E. Morais and G.F. Figueiredo, and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) and Federal University of São João Del Rei which provided a fellowship to J.T. Andrade.

References

- Allochio Filho JF, Roldi LL, Delarmelina M, Fiorot RG, Andrade JT, Aleixo AA, et al. Synthesis, *in vitro* antifungal activity and molecular modeling studies of new Mannich bases derived from lawsone. *J Braz Chem Soc.* 2016;27:2127–40.
- Araújo MGF, Pacífico M, Vilegas W, Dos Santos LC, Icely PA, Miró MS, et al. Evaluation of *Syngonanthus nitens* (Bong.) Ruhl. extract as antifungal and in treatment of vulvovaginal candidiasis. *Med Mycol.* 2003;51:673–82.
- Badiee P, Badali H, Boekhout T, Diba K, Moghadam AG, HossainiNasab A, et al. Antifungal susceptibility testing of *Candida* species isolated from the immunocompromised patients admitted to ten university hospitals in Iran: comparison of colonizing and infecting isolates. *BMC Infect Dis.* 2017;17:2–8.
- Bahri R, Saidane-Mosbah D, Rouabhia M. *Candida famata* modulates toll-like receptor, beta-defensin, and proinflammatory cytokine expression by normal human epithelial cells. *Cell Physiol.* 2010;222:209–18.
- Bowman SM, Free SJ. The structure and synthesis of the fungal cell wall. *Bioessays.* 2006;28:799–808.
- Carrara M, Donatti L, Damke E, Svidizinski TI, Consolaro ME, Batista MR. A new model of vaginal infection by *Candida albicans* in rats. *Mycopathologia.* 2010;170:331–8.
- Cassone A, Sobel JD. Experimental models of vaginal candidiasis and their relevance to human candidiasis. *Infect Immun.* 2016;84:1255–61.
- Chew SY, Than LTL. Vulvovaginal candidosis: contemporary challenges and the future of prophylactic and therapeutic approaches. *Mycoses.* 2016;59:262–73.
- Cho JW, Park K, Kweon GR, Jang BC, Baek WK, Suh MH, et al. Curcumin inhibits the expression of COX-2 in UVB-irradiated human keratinocytes (HaCaT) by inhibiting activation of AP-1: p38 MAP kinase and JNK as potential upstream targets. *Exp Mol Med.* 2005;37:186–92.
- Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts: approved standard. 3rd ed, CLSI document M27-A3 Wayne, Pa; 2008.
- Conti HR, Huppler AR, Whibley N, Gaffen SL. Animal models for candidiasis. *Curr Protoc Immunol.* 2014;105,19.6.1–19.6.17.
- Debata PR, Castellanos MR, Fata JE, Baggett S, Rajupet S, Szerszen A, et al. A novel curcumin-based vaginal cream Vacurin selectively eliminates apposed human cervical cancer cells. *Gynecol Oncol.* 2013;129:145–53.
- Dhawan S, Pal A, Ancha R, Bawankule DU, Yadav NP, Darokar MP, et al. Efficacy of CIM 1166, a combination of compounds derived from *Mentha* spp. in alleviating experimental vulvovaginal candidiasis in mice. *World J Microbiol Biotechnol.* 2009;25:161–3.
- Edwards RL, Luis PB, Varuzza PV, Joseph AL, Presley SH, Chaturvedi R, et al. The anti-inflammatory activity of curcumin is mediated by its oxidative metabolites. *J Biol Chem.* 2017;292:21243–52.
- Escalante A, Gattuso M, Perez P, Zacchino S. Evidence for the mechanism of action of the antifungal phytolaccoside B isolated from *Phytolacca tetramera* Hauman. *J Nat Prod.* 2008;71:1720–5.
- Fadus MC, Lau C, Bikhchandani J, Lynch HT. Curcumin: an age-old anti-inflammatory and anti-neoplastic agent. *J Tradit Complement Med.* 2017;7:339–46.
- Fidel P. History and update on host defense against vaginal candidiasis. *Immunology.* 2007;57:2–12.
- Giavini E, Menegola E. Are azole fungicides a teratogenic risk for human conceptus? *Toxicol Lett.* 2010;198:106–11.
- Guo Z, Li Q, Wang G, Dong F, Zhou H, Zhang J. Synthesis, characterization, and antifungal activity of novel inulin derivatives with chlorinated benzene. *Carbohydr Polym.* 2014;99:469–73.
- He X, Ma Y, Yi G, Wu J, Zhou L, Guo H. Chemical composition and antifungal activity of *Carica papaya* Linn. seed essential oil against *Candida* spp. *Lett Appl Microbiol.* 2017;64:350–4.
- Hewlings SJ, Kalman DS. Curcumin: a review of its effects on human health. *Foods.* 2017;6:1–11.
- Hong L, Bose J, Ju J, Ryu JH, Chen X, Sang S, et al. Modulation of arachidonic acid metabolism by curcumin and related beta-diketone derivatives: effects on cytosolic phospholipase A(2), cyclooxygenases and 5-lipoxygenase. *Carcinogenesis.* 2004;25:1671–9.
- Kyriakidis I, Tragiannidis A, Munchen S, Groll AH. Clinical hepatotoxicity associated with antifungal agents. *Expert Opin Drug Saf.* 2017;16:149–65.
- Lee W, Lee DG. An antifungal mechanism of curcumin lies in membrane-targeted action within *Candida albicans*. *Life.* 2014;66:780–5.
- Logan-Smith MJ, Lockyer PJ, East JM, Lee AG. Curcumin, a molecule that inhibits the Ca²⁺-ATPase of sarcoplasmic reticulum but increases the rate of accumulation of Ca²⁺. *J Biol Chem.* 2001;276:46905–11.
- Martins CVB, da Silva DL, Neres ATM, Magalhães TF, Watanabe GA, Modolo LV, et al. Curcumin as a promising antifungal of clinical interest. *J Antimicrob Chemother.* 2009;63:337–9.
- Miró MS, Rodríguez E, Vigezzi C, Icely PA, García LN, Painetti N, et al. Contribution of TLR2 pathway in the pathogenesis of vulvovaginal candidiasis. *Pathogens and Disease.* 2017;75, ftx096.
- Moghadamtousi SZ, Kadir HA, Hassandarvish P, Tajik H, Abubakar S, Zandi K. A review on antibacterial, antiviral, and antifungal activity of curcumin. *Biomed Res Int.* 2014;2014:186864.
- Musthafa KS, Hmoteh J, Thamjarungwong B, Voravuthikunchai SP. Antifungal potential of eugenyl acetate against clinical isolates of *Candida* species. *Microb Pathog.* 2016;99:19–29.
- Neelofar K, Shreaz S, Rimple B, Muralidhar S, Nikhat M, Khan LA. Curcumin as a promising anticandidal of clinical interest. *Can J Microbiol.* 2011;57:204–10.
- Netea MG, Kullberg BJ. Epithelial sensing of fungal invasion. *Cell Host Microbe.* 2010;8:219–23.
- Perfekt JR. The antifungal pipeline: a reality check. *Nat Rev Drug Discov.* 2017;12:1–14.
- Peters BM, Yano J, Noverr MC, Fidel PL Jr. *Candida* vaginitis: when opportunism knocks, the host responds. *PLoS Pathog.* 2014;10:1–4.
- Prasad S, Aggarwal BB. Turmeric, the golden spice: from traditional medicine to modern medicine. In: Benzie IFF, Wachtel-Galor S, editors. *Source herbal medicine: biomolecular and clinical aspects.* Boca Raton, FL: CRC Press/Taylor & Francis; 2011 [chapter 13].
- Ramos MAS, Toledo LG, Calixto GM, Bonifácio BV, Araújo MGF, Santos LC, et al. *Syngonanthus nitens* Bong (Ruhl.)-loaded nanostructured system for vulvovaginal candidiasis treatment. *Int J Mol Sci.* 2016;17:1–19.

37. Sharma M, Manoharlal R, Puri N, Prasad R. Antifungal curcumin induces reactive oxygen species and triggers an early apoptosis but prevents hyphae development by targeting the global repressor TUP1 in *Candida albicans*. Biosci Rep. 2010;30:391–404.
38. Silva S, Negri M, Henriques M, Oliveira R, Williams DW, Azeredo J. *Candida glabrata*, *Candida parapsilosis* and *Candida tropicalis*: biology, epidemiology, pathogenicity and antifungal resistance. FEMS Microbiol Rev. 2012;36:288–305.
39. Sobel JD. Recurrent vulvovaginal candidiasis. Am J Obstet Gynecol. 2015;214:15–21.
40. Tapia CV, Hermosilla G, Fortes P, Alburquenque C, Bucarey S, Salinas H, et al. Genotyping and persistence of *Candida albicans* from pregnant women with vulvovaginal candidiasis. Mycopathologia. 2017;182:339–47.
41. Teinkela JEM, Noundod XS, Fannang S, Meyer F, Vardamides JC, Mpondo EM, et al. In vitro antimicrobial activity of the methanol extract and compounds from the wood of *Ficus elastic* Roxb. ex Hornem aerial roots. S Afr J Bot. 2017;111:302–6.
42. Tverdek FP, Kofteridis D, Kontoyiannis DP. Antifungal agents and liver toxicity: a complex interaction. Expert Rev Anti Infect Ther. 2016;14:765–76.
43. Udayalaxmi SJ, Jacod S, D'Souza D. Comparison between virulence factors of *Candida albicans* and non-*albicans* species of *Candida* isolated from genitourinary tract. J Clin Diagn Res. 2014;8:DC15–7.
44. Wiederhold NP. Antifungal resistance: current trends and future strategies to combat. Infect Drug Resist. 2017;10:249–59.
45. Wong SSW, Kao RYT, Yuen KY, Wang Y, Yang D, Samaranyake LP, et al. In vitro and in vivo activity of a novel antifungal small molecule against *Candida* infections. PLoS ONE. 2014;9:1–17.
46. Yapar N. Epidemiology and risk factors for invasive candidiasis. Ther Clin Risk Manag. 2014;10:95–105.
47. Zeng H, Tian J, Zheng Y, Ban X, Zeng J, Mao Y, et al. In vitro and in vivo activities of essential oil from the seed of *Anethum graveolens* L. against *Candida* spp. Evid Based Complement Alternat Med. 2011;1–8.
48. Zhang L, Zong H, Lu H, Gong J, Ma F. Discovery of novel anti-tumor curcumin analogues from the optimization of curcumin scaffold. Med Chem Res. 2017;26:2468–76.